58
Views
14
CrossRef citations to date
0
Altmetric
Original

Electron spin resonance and spin trapping technique provide direct evidence that edaravone prevents acute ischemia–reperfusion injury of the liver by limiting free radical-mediated tissue damage

, , , , , & show all
Pages 579-588 | Received 06 Nov 2005, Published online: 07 Jul 2009
 

Abstract

A novel free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), is used for the treatment of acute ischemic stroke and is protective in several animal models of organ injury. We tested whether edaravone is protective against acute liver warm ischemia/reperfusion injury in the rat by acting as a radical scavenger. When edaravone was administered prior to ischemia and at the time of initiation of the reperfusion, liver injury was markedly reduced. Production of oxidants in the liver in this model was assessed in vivo by spin-trapping/electron spin resonance (ESR) spectroscopy. Ischemia/reperfusion caused an increase in free radical adducts rapidly, an effect markedly blocked by edaravone. Furthermore, edaravone treatment blunted ischemia/reperfusion-induced elevation in pro-inflammatory cytokines, infiltration of leukocytes and lipid peroxidation in the liver. These results demonstrate that edaravone is an effective blocker of free radicals in vivo in the liver after ischemia/reperfusion, leading to prevention of organ injury by limiting the deleterious effects of free radicals.

Abbreviations
TNFα=

tumor necrosis factor α

IL=

interleukin

ALT=

alanine aminotransferase

ESR=

electron spin resonance

HA=

hyaluronic acid

ROS=

reactive oxygen species

EDA=

edaravone

POBN=

α-(4-pyridyl-1-oxide)-N-tert-butylnitrone

Abbreviations
TNFα=

tumor necrosis factor α

IL=

interleukin

ALT=

alanine aminotransferase

ESR=

electron spin resonance

HA=

hyaluronic acid

ROS=

reactive oxygen species

EDA=

edaravone

POBN=

α-(4-pyridyl-1-oxide)-N-tert-butylnitrone

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.